LGI1 and encephalitis: A total of 312 patients with AE were included: 197 (63.1%) with anti‐NMDAR encephalitis, 71 (22.8%) with anti‐LGI1 encephalitis, 20 (6.4%) with anti‐GABAbR encephalitis, 10 (3.2%) with anti‐CASPR2 encephalitis, 10 (3.2%) with anti‐GAD65 encephalitis, and 4 (1.3%) with anti‐AMPAR2 encephalitis.